Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessTvardi - About the company
Tvardi is a series B company based in Houston (United States), founded in 2017 by Ron DePinho and David J Tweardy. It operates as a Developer of small molecule based therapeutics for cancer treatment. Tvardi has raised $83M in funding. The company has 3158 active competitors, including 1076 funded and 737 that have exited. Its top competitors include companies like Moderna, Jazz Pharmaceuticals and BeiGene.
Company Details
Developer of small molecule-based therapeutics for cancer treatment. The company's lead product candidate TTI-101 used against oral cancer is an inhibitor of signal transducer and activator of transcription, STAT3, a protein in the cytoplasm of cancer cells. The product is in Phase 1 clinical trials. Other products of the company which includes TTI-101 against cachexia and TTI-102 against oral cancer are in pre-clinical trials.
- Website
- tvarditherapeutics.com
- Social
- Email ID
- *****@tvardi.com
Key Metrics
Founded Year
2017
Location
Houston, United States
Stage
Series B
Total Funding
$83M in 4 rounds
Latest Funding Round
Investors
Ranked
184th among 3158 active competitors
Legal entities associated with Tvardi
Tvardi is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Dec 11, 2018 | - | - |
Get your free copy of Tvardi's company profile
Tvardi's funding and investors
Filter this listTvardi has raised a total funding of $83M over 4 rounds. Its first funding round was on Sep 18, 2018. Its latest funding round was a Series B round on Jun 15, 2021 for $74M. 3 investors participated in its latest round, which includes ArrowMark Partners, NIH, National Cancer Institute and HHS.
Tvardi has 11 institutional investors including ArrowMark Partners, NIH and National Cancer Institute.
Here is the list of recent funding rounds of Tvardi:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jun 15, 2021 | $74M | Series B | 3166421 | 5226661 | |
Jul 26, 2020 | $5M | Grant (prize money) | 7099047 | 8082446 | |
Sep 20, 2018 | $9M | Series A | 5767874 | 5111849 | - |
Access funding benchmarks and valuations. Sign up today!View details of Tvardi's funding rounds and investors
Tvardi's founders and board of directors
Founder? Claim ProfileThe founders of Tvardi are Ron DePinho and David J Tweardy.
View details of Tvardi's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Tvardi's Competitors and alternates
Top competitors of Tvardi include Moderna, Jazz Pharmaceuticals and BeiGene. Here is the list of Top 10 competitors of Tvardi, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
2nd | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 80/100 | |
3rd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 78/100 | |
4th | Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 77/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer. | $317M | 73/100 | |
6th | Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | 72/100 | |
7th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | 71/100 | |
8th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 71/100 | |
9th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 71/100 | ||
10th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 71/100 | |
184th | Tvardi 2017, Houston (United States), Series B | Developer of small molecule based therapeutics for cancer treatment | $83M | 56/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Tvardi's competitors? Click here to see the top ones
Tvardi's Investments and acquisitions
Tvardi has made no investments or acquisitions yet.
Reports related to Tvardi
Here is the latest report on Tvardi's sector:
News related to Tvardi
Filter this listMedia has covered Tvardi for a total of 7 events in the last 1 year, 1 of them has been about company updates.
•
Tvardi Therapeutics files to sell 2.08M shares of common stock for holdersSeeking Alpha•May 30, 2025•Tvardi
•
•
•
Cara Therapeutics Announces 1-for-3 Reverse Stock Split and Merger with Tvardi TherapeuticsGlobeNewswire•Apr 14, 2025•Cara Therapeutics, Tvardi
•
•
Rigrodsky Law, P.A. Is Investigating Cara Therapeutics, Inc. MergerNewsfile•Dec 19, 2024•Rigrodsky Law, Cara Therapeutics, Tvardi
•
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger AgreementForexTV•Dec 18, 2024•Tvardi, Cara Therapeutics
•
Tvardi Therapeutics Appoints Sujal Shah As Chairman And Adds Shaheen Wirk To The Board Of DirectorsBusiness Wire•Mar 26, 2024•Tvardi
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Tvardi
Explore our recently published companies